SUBOXONE Drug Patent Profile

When do Suboxone patents expire, and when can generic versions of Suboxone launch?

Suboxone is a drug marketed by Indivior and is included in two NDAs. There are three patents protecting this drug and three Paragraph IV challenges.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in SUBOXONE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Suboxone

A generic version of SUBOXONE was approved as buprenorphine hydrochloride; naloxone hydrochloride by ACTAVIS ELIZABETH on February 22^nd, 2013.

Summary for SUBOXONE

International Patents:	32
US Patents:	3
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	30
Clinical Trials:	100
Drug Prices:	Drug price information for SUBOXONE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SUBOXONE
What excipients (inactive ingredients) are in SUBOXONE?	SUBOXONE excipients list
DailyMed Link:	SUBOXONE at DailyMed

See drug prices for SUBOXONE

See drug sales revenues for SUBOXONE

Recent Clinical Trials for SUBOXONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Indivior Inc.	PHASE2
National Institute on Drug Abuse (NIDA)	PHASE4
Erin Winstanley	PHASE4

See all SUBOXONE clinical trials

Pharmacology for SUBOXONE

Drug Class	Opioid Antagonist Partial Opioid Agonist
Mechanism of Action	Opioid Antagonists Partial Opioid Agonists

Paragraph IV (Patent) Challenges for SUBOXONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUBOXONE	Sublingual Film	buprenorphine hydrochloride; naloxone hydrochloride	12 mg/3 mg	022410	1	2013-05-14
SUBOXONE	Sublingual Film	buprenorphine hydrochloride; naloxone hydrochloride	2 mg/0.5 mg* and 8 mg/2 mg	022410	1	2012-10-15
SUBOXONE	for Injection	buprenorphine hydrochloride; naloxone hydrochloride	500 mg/vial	020733	2	2009-01-26

US Patents and Regulatory Information for SUBOXONE

SUBOXONE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-001	Aug 30, 2010	AB	RX	Yes	No	9,687,454		Y
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-002	Aug 30, 2010	AB	RX	Yes	No	8,475,832		Y
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-003	Aug 10, 2012	AB	RX	Yes	No	9,687,454		Y
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-004	Aug 10, 2012	AB	RX	Yes	Yes	11,135,216		Y
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-002	Aug 30, 2010	AB	RX	Yes	No	9,687,454		Y

Expired US Patents for SUBOXONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-003	Aug 10, 2012	10,285,910
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-002	Aug 30, 2010	9,855,221
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-004	Aug 10, 2012	8,603,514
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-001	Aug 30, 2010	10,285,910
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-003	Aug 10, 2012	8,017,150

International Patents for SUBOXONE

When does loss-of-exclusivity occur for SUBOXONE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Denmark

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

New Zealand

Peru

Russian Federation

Singapore

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SUBOXONE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010279440	Sublingual and buccal film compositions
Singapore	178265	SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
Japan	4795962
Australia	2011253023	Film compositions for delivery of actives
China	101321511	Topical film compositions for delivery of actives

SUBOXONE: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

SUBOXONE (buprenorphine and naloxone) is a medication-assisted treatment (MAT) for opioid use disorder (OUD). Its market trajectory is influenced by patent expirations, generic competition, regulatory shifts, and the growing recognition of OUD as a public health crisis. This analysis examines the intellectual property landscape, market performance, and future outlook for SUBOXONE.

What is SUBOXONE's Patent Status?

SUBOXONE's primary patent protection has expired, enabling generic market entry. The original U.S. patent for SUBOXONE film was U.S. Patent No. 8,900,978, filed on May 1, 2008, and issued on December 1, 2014. This patent has since expired.

Additional patents related to specific formulations, manufacturing processes, and methods of use may have existed or been filed. However, the key composition of matter patent has lapsed.

• Original Manufacturer: Indivior PLC.
• Original Formulation: Sublingual tablet and later a sublingual film.
• Key Active Ingredients: Buprenorphine (opioid partial agonist) and Naloxone (opioid antagonist).
• Expiration Timeline: The primary patents for the sublingual film formulation expired in 2023.

The expiration of these foundational patents has opened the door for multiple generic manufacturers to produce and market their own versions of buprenorphine/naloxone products. This has significantly impacted SUBOXONE's market share and pricing.

How Has Generic Competition Affected SUBOXONE's Sales?

The introduction of generic buprenorphine/naloxone products has led to a substantial decline in SUBOXONE's revenue. Generic drugs typically enter the market at significantly lower price points, forcing brand-name manufacturers to compete on cost or risk losing substantial market share.

• Revenue Decline: Indivior reported a significant drop in SUBOXONE film net revenue in the United States following the launch of its first generic competitors. For example, in the first quarter of 2023, U.S. SUBOXONE film net revenue decreased by 91% to $21 million compared to the prior year period, primarily due to generic competition [1].
• Market Share Erosion: SUBOXONE's market dominance has diminished as generics gained traction. While SUBOXONE was once the leading product in the buprenorphine/naloxone market, its share has been considerably reduced.
• Pricing Pressure: The availability of multiple generic alternatives has created intense pricing pressure, driving down the average selling price for buprenorphine/naloxone products. This affects both brand and generic manufacturers.
• Generic Entry: Multiple pharmaceutical companies, including Teva Pharmaceuticals, Dr. Reddy's Laboratories, and Hikma Pharmaceuticals, have launched generic versions of buprenorphine/naloxone films and tablets.

The financial impact on Indivior has been profound, necessitating strategic shifts to focus on newer products and markets outside of the U.S. SUBOXONE's financial trajectory in the U.S. is now characterized by a declining revenue stream from its original franchise.

What is the Current Market Size for Buprenorphine/Naloxone Products?

The overall market for buprenorphine/naloxone products remains substantial due to the ongoing opioid crisis and increasing access to OUD treatment. While SUBOXONE's specific contribution has decreased, the combined market for all buprenorphine/naloxone formulations is significant.

• U.S. Market Value: Prior to widespread generic entry, the U.S. market for buprenorphine/naloxone (primarily SUBOXONE) generated billions of dollars annually. Following genericization, the total market value has shifted, with a larger portion attributed to generic sales.
• Prescription Volume: Millions of prescriptions for buprenorphine/naloxone are filled annually in the U.S., reflecting the widespread need for OUD treatment.
• Growth Drivers: Increased awareness of OUD, policy initiatives to expand access to treatment, and the Schedule III classification of buprenorphine (allowing for easier prescribing by licensed physicians) contribute to market demand.
• Competitive Landscape: The market is now highly fragmented with numerous generic manufacturers competing with Indivior's branded SUBOXONE and its authorized generic.

Estimating the precise current market size for all buprenorphine/naloxone products is challenging due to the rapid shifts and proprietary data held by manufacturers. However, it remains a multi-billion dollar segment within the U.S. pharmaceutical market, driven by treatment demand rather than a single product's dominance.

What are the Regulatory Factors Influencing Buprenorphine/Naloxone Access?

Regulatory policies play a crucial role in both facilitating and constraining access to buprenorphine/naloxone products. Recent regulatory changes have aimed to increase treatment availability, while historical regulations presented barriers.

• X-Waiver Elimination: In March 2023, the U.S. Department of Health and Human Services (HHS) eliminated the requirement for healthcare providers to obtain a special waiver (the "X-waiver") to prescribe buprenorphine for OUD [2]. This policy change significantly reduces a major barrier to prescribing, potentially increasing patient access and demand for buprenorphine/naloxone.
• DEA Scheduling: Buprenorphine is classified as a Schedule III controlled substance under the Controlled Substances Act. This classification allows for prescribing by any DEA-registered practitioner without the need for specific registration for Schedule II substances.
• FDA Approval: Products containing buprenorphine and naloxone require FDA approval. Different formulations (tablets, films) and strengths are approved for specific indications.
• DEA Diversion Control: The Drug Enforcement Administration (DEA) oversees controlled substances, including buprenorphine, to prevent diversion and abuse. Regulations regarding storage, dispensing, and record-keeping are in place.
• Medicaid and Insurance Coverage: The availability and formulary status of buprenorphine/naloxone products on Medicaid and private insurance plans significantly impact patient access and out-of-pocket costs. Mandates for coverage of OUD treatments are increasing.
• Harm Reduction Policies: Broader public health initiatives promoting harm reduction and evidence-based addiction treatment tend to support increased utilization of medications like buprenorphine/naloxone.

The elimination of the X-waiver is a significant regulatory development expected to boost the market for buprenorphine/naloxone products by enabling more prescribers to offer treatment.

What is Indivior's Strategy Post-SUBOXONE Patent Expiration?

Indivior PLC has pivoted its strategy to focus on product diversification and geographic expansion following the loss of market exclusivity for SUBOXONE in the U.S.

• New Product Development: Indivior is investing heavily in its pipeline, particularly in areas beyond OUD, and in newer formulations or delivery methods for OUD treatment. This includes exploring novel molecules and formulations designed to address unmet needs or provide differentiated treatment options.
• Geographic Diversification: The company is increasing its focus on international markets where patent protection for SUBOXONE may still be in place or where generic competition has not yet significantly impacted sales.
• Authorized Generic: Indivior launched an authorized generic of SUBOXONE film, allowing it to capture a portion of the generic market revenue and maintain a presence as generic competition emerged. This is a common strategy for brand manufacturers to mitigate the impact of patent expiration.
• Portfolio Management: The company is managing its portfolio to transition resources from the declining SUBOXONE franchise to newer growth drivers. This involves strategic sales and marketing efforts for its other approved products.
• Focus on Buvidal/Brixadi: Indivior's long-acting injectable buprenorphine products, Buvidal (Europe, Australia) and Brixadi (U.S.), represent a key part of its future strategy, offering a differentiated treatment option for OUD. These products aim to improve adherence and offer a longer-acting alternative to daily dosing.

Indivior's strategy is to offset the substantial revenue decline from SUBOXONE in the U.S. by developing and commercializing new treatments and expanding its global reach.

What is the Future Outlook for Buprenorphine/Naloxone Treatment?

The future outlook for buprenorphine/naloxone as a treatment for OUD is positive, driven by increased demand, policy support, and innovation in delivery systems.

• Growing Treatment Needs: The persistent opioid crisis indicates a sustained and significant demand for effective OUD treatments like buprenorphine/naloxone.
• Policy Tailwinds: The elimination of the X-waiver is expected to lead to broader physician adoption and increased patient access. Continued policy support for MAT is anticipated.
• Innovation in Formulations: Development of long-acting injectables and other novel delivery systems (e.g., implants, patches) aims to improve patient adherence, reduce diversion risk, and offer more convenient treatment options. These innovations can create new market opportunities.
• Market Competition: While generic competition will continue to drive down prices for traditional formulations, it also increases affordability and accessibility, expanding the overall number of patients treated.
• Focus on Patient Outcomes: An increasing emphasis on patient outcomes, adherence, and reduced relapse rates will favor medications that demonstrate these benefits.
• Integration of Care: The trend towards integrating OUD treatment with primary care and mental health services will likely increase the utilization of accessible MAT options like buprenorphine/naloxone.

The market for buprenorphine/naloxone products will continue to evolve, with increased volume driven by greater accessibility and policy support, offset by ongoing price pressures from generic competition. Innovation in product delivery will be a key differentiator.

Key Takeaways

• SUBOXONE's primary U.S. patents have expired, leading to significant generic competition and a drastic reduction in Indivior's SUBOXONE film revenue.
• The U.S. buprenorphine/naloxone market, encompassing all formulations, remains a multi-billion dollar segment due to the ongoing opioid crisis and increased treatment access.
• Regulatory changes, notably the elimination of the X-waiver for buprenorphine prescribing, are poised to increase patient access and overall demand for buprenorphine/naloxone products.
• Indivior is pursuing a strategy of product diversification, geographic expansion, and developing novel OUD treatments, such as long-acting injectables, to offset declining SUBOXONE sales.
• The future outlook for buprenorphine/naloxone treatment is positive, driven by persistent demand, supportive policies, and innovation in drug delivery systems, despite ongoing generic price pressures.

Frequently Asked Questions

1. What is the primary indication for SUBOXONE?

SUBOXONE is indicated for the treatment of opioid use disorder (OUD), including induction of transition from other opioids and maintenance treatment.

2. How does naloxone in SUBOXONE work?

Naloxone is included in SUBOXONE to deter misuse and diversion. If SUBOXONE is injected, the naloxone can precipitate opioid withdrawal symptoms in individuals dependent on opioids. If taken as directed (sublingually), the naloxone is poorly absorbed and has minimal effect, allowing the buprenorphine to exert its therapeutic action.

3. Are there different forms of buprenorphine/naloxone available besides SUBOXONE film?

Yes, buprenorphine/naloxone is available in various formulations, including sublingual tablets and sublingual films, produced by multiple generic manufacturers in addition to Indivior's brand and authorized generic. Long-acting injectable formulations are also available.

4. What was the impact of the X-waiver elimination on buprenorphine prescribing?

The elimination of the X-waiver in March 2023 removed a significant regulatory barrier, allowing any DEA-registered practitioner to prescribe buprenorphine for OUD without needing a special waiver. This is expected to increase the number of prescribers and patients receiving buprenorphine-based treatment.

5. What is Indivior's authorized generic strategy?

Indivior launched an authorized generic of SUBOXONE film to compete directly in the generic market following patent expirations. This allows the company to capture a share of the generic revenue and maintain a presence as competitors enter the market.

---

[1] Indivior PLC. (2023). First Quarter 2023 Results Announcement. [2] U.S. Department of Health and Human Services. (2023, March 10). HHS Eliminates Controlled Substance Sig Waiver Requirement for Buprenorphine. Retrieved from https://www.hhs.gov/about/news/2023/03/10/hhs-eliminates-controlled-substance-sig-waiver-requirement-buprenorphine.html